scholarly journals UKPDS 31: Hepatocyte nuclear factor-1alpha (the MODY3 gene) mutations in late onset Type II diabetic patients in the United Kingdom

Diabetologia ◽  
1999 ◽  
Vol 42 (1) ◽  
pp. 120-121 ◽  
Author(s):  
Not Available Not Available
Keyword(s):  
United Kingdom ◽  
Late Onset ◽  
Gene Mutations ◽  
Diabetic Patients ◽  
Nuclear Factor ◽  
Type Ii ◽  
Hepatocyte Nuclear Factor ◽  
Onset Type ◽  
The United Kingdom

scholarly journals Variants in the hepatocyte nuclear factor-1alpha and -4alpha genes in Finnish and Chinese subjects with late-onset type 2 diabetes

Diabetes Care ◽  
2000 ◽  
Vol 23 (10) ◽  
pp. 1533-1538 ◽  
Author(s):  
J. Rissanen ◽  
H. Wang ◽  
R. Miettinen ◽  
P. Karkkainen ◽  
P. Kekalainen ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Late Onset ◽  
Nuclear Factor ◽  
Hepatocyte Nuclear Factor ◽  
Onset Type ◽  
Chinese Subjects

Novel Genetic Variations and Haplotypes of Hepatocyte Nuclear Factor 4α(HNF4A) Pound in Japanese Type II Diabetic Patients

2006 ◽  
Vol 21 (4) ◽  
pp. 337-346 ◽  
Author(s):  
Hiromi Fukushima-Uesaka ◽  
Yoshiro Saito ◽  
Keiko Maekawa ◽  
Mayumi Saeki ◽  
Naoyuki Kamatani ◽  
...  
Keyword(s):  
Genetic Variations ◽  
Diabetic Patients ◽  
Nuclear Factor ◽  
Type Ii ◽  
Hepatocyte Nuclear Factor ◽  
Hepatocyte Nuclear Factor 4Α

ELFIN, the United Kingdom preterm lactoferrin trial: interpretation and future questions

2020 ◽  
Author(s):  
Janet Elizabeth Berrington ◽  
William McGuire ◽  
NIcholas David Embleton
Keyword(s):  
United Kingdom ◽  
Preterm Infants ◽  
Late Onset ◽  
Disease Onset ◽  
Intervention Group ◽  
Control Group ◽  
Bovine Lactoferrin ◽  
The United Kingdom ◽  
Late Onset Sepsis ◽  
The Uk

Previous studies suggested that supplemental bovine lactoferrin (BLF) given to preterm infants (<32 weeks gestation) may reduce late onset sepsis (LOS) and necrotising enterocolitis (NEC), but have been underpowered. The Enteral Lactoferrin in Neonates (ELFIN) study, performed in the United Kingdom (UK), aimed to further address this issue with a well powered double blinded placebo controlled trial of >2200 preterm infants. ELFIN did not demonstrate a reduction in LOS or NEC, or several other clinically important measures. 316 (29%) of 1093 infants in the intervention group developed late-onset sepsis versus 334 (31%) of 1089 in the control group with an adjusted risk ratio of 0·95 (95% CI 0·86–1·04; p=0· 233). Reasons for the differences in ELFIN trial results and other studies may include population differences, the routine use of antifungals in the UK, timing of administration of the lactoferrin in relation to disease onset, or specific properties of the lactoferrin used in different trials. Further exploration is being undertaken in the UK NIHR funded Mechanisms Affecting the Guts of Preterm Infants in Enteral feeding trials (MAGPIE) study, for which results should be available soon.

scholarly journals A Novel -192c/g Mutation in the Proximal P2 Promoter of the Hepatocyte Nuclear Factor-4  Gene (HNF4A) Associates With Late-Onset Diabetes

Diabetes ◽  
2006 ◽  
Vol 55 (6) ◽  
pp. 1869-1873 ◽  
Author(s):  
J. Ek ◽  
S. P. Hansen ◽  
M. Lajer ◽  
C. Nicot ◽  
T. W. Boesgaard ◽  
...  
Keyword(s):  
Late Onset ◽  
Nuclear Factor ◽  
Hepatocyte Nuclear Factor ◽  
Onset Diabetes ◽  
P2 Promoter ◽  
Hepatocyte Nuclear Factor 4

scholarly journals Study protocol: optimising newborn nutrition during and after neonatal therapeutic hypothermia in the United Kingdom: observational study of routinely collected data using propensity matching

BMJ Open ◽  
2018 ◽  
Vol 8 (10) ◽  
pp. e026739 ◽  
Author(s):  
Cheryl Battersby ◽  
Nick Longford ◽  
Mehali Patel ◽  
Ella Selby ◽  
Shalini Ojha ◽  
...  
Keyword(s):  
United Kingdom ◽  
Therapeutic Hypothermia ◽  
Late Onset ◽  
Standard Of Care ◽  
Blood Stream ◽  
Research Database ◽  
Population Database ◽  
Scientific Publications ◽  
Link Type ◽  
The United Kingdom

IntroductionTherapeutic hypothermia is standard of care for infants born ≥36 weeks gestation with hypoxic ischaemic encephalopathy (HIE); consensus on optimum nutrition during therapeutic hypothermia is lacking. This results in variation in enteral feeding and parenteral nutrition (PN) for these infants. In this study, we aim to determine the optimum enteral nutrition and PN strategy for newborns with HIE during therapeutic hypothermia.Methods and analysisWe will undertake a retrospective cohort study using routinely recorded electronic patient data held on the United Kingdom (UK) National Neonatal Research Database (NNRD). We will extract data from infants born ≥36 weeks gestational age between 1 January 2008 and 31 December 2016, who received therapeutic hypothermia for at least 72 hours or died during therapeutic hypothermia, in neonatal units in England, Wales and Scotland. We will form matched groups in order to perform two comparisons examining: (1) the risk of NEC between infants enterally fed and infants not enterally fed, during therapeutic hypothermia; (2) the risk of late-onset blood stream infections between infants who received intravenous dextrose without any PN and infants who received PN, during therapeutic hypothermia. The following secondary outcomes will also be examined: survival, length of stay, breast feeding at discharge, hypoglycaemia, time to full enteral feeds and growth. Comparison groups will be matched on demographic, maternal, infant and organisational factors using propensity score matching.Ethics and disseminationIn this study, we will use deidentifed data held in the NNRD, an established national population database; parents can opt out of their baby’s data being held in the NNRD. This study holds study-specific Research Ethics Committee approval (East Midlands Leicester Central, 17/EM/0307). These results will help inform optimum nutritional management in infants with HIE receiving therapeutic hypothermia; results will be disseminated through conferences, scientific publications and parent-centred information produced in partnership with parents.Trial registration numberNCT03278847; pre-results,ISRCTN47404296; pre-results.

Delayed or late-onset type II glycogenosis with globular inclusions

2005 ◽  
Vol 110 (2) ◽  
pp. 151-157 ◽  
Author(s):  
Mehar C. Sharma ◽  
Christoph Schultze ◽  
Arpad von Moers ◽  
Gisela Stoltenburg-Didinger ◽  
Yoon S. Shin ◽  
...  
Keyword(s):  
Late Onset ◽  
Type Ii ◽  
Onset Type ◽  
Type Ii Glycogenosis

scholarly journals Hepatocyte nuclear factor-6: associations between genetic variability and Type II diabetes and between genetic variability and estimates of insulin secretion

Diabetologia ◽  
1999 ◽  
Vol 42 (8) ◽  
pp. 1011-1016 ◽  
Author(s):  
A. M. Møller ◽  
J. Ek ◽  
S. M. Durviaux ◽  
S. A. Urhammer ◽  
J. O. Clausen ◽  
...  
Keyword(s):  
Insulin Secretion ◽  
Genetic Variability ◽  
Type Ii Diabetes ◽  
Nuclear Factor ◽  
Type Ii ◽  
Hepatocyte Nuclear Factor
Sign in / Sign up

Export Citation Format

Share Document